— Zoetis Inc. (NYSE: ZTS) reported its fourth-quarter 2019 adjusted earnings of $0.92 per share versus $0.88 expected.
— Revenues grew 7% to $1.7 billion versus $1.64 billion expected. On an operational basis, revenue, excluding the impact of foreign exchange, increased by 9%.
— The US segment revenue rose by 6% as growth in key dermatology portfolio across both the Apoquel and Cytopoint brands drove sales of companion animal products higher by 15%.
— International revenue grew 9% on higher sales across key dermatology portfolio and in certain parasiticides, including Simparica and the Revolution/Stronghold franchise, as well as growth across key markets in Western Europe and in China.
— For full-year 2020, the company expects operational growth of 7% to 9.5% in revenue and 8% to 11% in adjusted net income.
— For the full year 2020, the company expects revenue in the range of $6.65-6.8 billion, EPS of $3.53-3.65 and adjusted EPS of $3.90-4.00. The consensus estimates EPS of $4.01 on revenue of $6.7 billion.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Key highlights from Deere & Co.’s (DE) Q4 2024 earnings results
Deere & Company (NYSE: DE) reported its fourth quarter 2024 earnings results today. Worldwide net sales and revenues decreased 28% year-over-year to $11.14 billion. Net income was $1.24 billion, or
NVDA Earnings: Nvidia Q3 profit jumps, beats estimates
NVIDIA Corporation (NASDAQ: NVDA) on Wednesday reported a sharp increase in adjusted profit and revenue for the third quarter of 2025. Earnings also topped analysts' estimates. The tech firm’s revenues
Lowe’s Companies (LOW): A few points to note about the Q3 2024 performance
Shares of Lowe’s Companies, Inc. (NYSE: LOW) rose over 1% on Wednesday. The stock has gained 8% over the past three months. The company delivered better-than-expected earnings results for the
